Fig. 11.

a Exemplary immunoblots of mTOR, pmTOR, p70S6K, pp70S6K, GluA1, PSD-95, and β-actin from the PFC of vehicle-treated group (V), ketamine (3 mg/kg) + LY341495 (0.3 mg/kg)-treated group (K + L), and ketamine (10 mg/kg)-treated group (K). The tissue was collected 40 min after drugs administration. b Exemplary immunoblots of mTOR, pmTOR, p70S6K, pp70S6K, GluA1, PSD-95, and β-actin from hippocampus of vehicle-treated group (V), ketamine (3 mg/kg) + LY341495 (0.3 mg/kg)-treated group (K + L), and ketamine (10 mg/kg)-treated group (K). The tissue was collected 40 min after drugs administration. c Exemplary immunoblots of GluR1, PSD95, and β-actin from the PFC of vehicle-treated group (V), ketamine (3 mg/kg) + LY341495 (0.3 mg/kg)-treated group (K + L), and ketamine (10 mg/kg)-treated group (K) The tissue was collected 24 h after drug administration. d Exemplary immunoblots of GluR1, PSD95, and β-actin from hippocampus of vehicle-treated group (VEH), ketamine (3 mg/kg) + LY341495 (0.3 mg/kg)-treated group (KET + LY), and ketamine (10 mg/kg)-treated group (KET 10). The tissue was collected 24 h after drug administration